Clinical and Dermoscopic Evaluation of the Efficacy of Melasma Treatment With Oral Tranexamic Acid

The study evaluated the efficacy and safety of oral tranexamic acid (TA) for treating melasma in 40 female patients aged 27-50 years over 3 months. Patients took 250 mg of TA twice daily, resulting in significant improvement in melasma, with 47.5% experiencing an excellent response, 30% a very good response, and 22.5% a good response. Dermoscopic evaluation indicated reduced pigmentation and erythema in 67.5% of patients. The study concluded that oral TA is a safe and effective treatment for melasma, with no risk of post-inflammatory hyperpigmentation, thrombotic, or bleeding tendencies, and no adverse effects reported.